PSD3 downregulation confers protection against fatty liver disease

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • R.M. Mancina - (Author)
  • K. Sasidharan - (Author)
  • A. Lindblom - (Author)
  • Ying Wei - , Ionis Pharmaceuticals (Author)
  • E. Ciociola - (Author)
  • O. Jamialahmadi - (Author)
  • P. Pingitore - (Author)
  • A.-C. Andréasson - (Author)
  • G. Pellegrini - (Author)
  • G. Baselli - (Author)
  • V. Männistö - (Author)
  • J. Pihlajamäki - (Author)
  • V. Kärjä - (Author)
  • S. Grimaudo - (Author)
  • I. Marini - (Author)
  • M. Maggioni - (Author)
  • B. Becattini - (Author)
  • F. Tavaglione - (Author)
  • C. Dix - (Author)
  • M. Castaldo - (Author)
  • S. Klein - (Author)
  • M. Perelis - (Author)
  • F. Pattou - (Author)
  • D. Thuillier - (Author)
  • V. Raverdy - (Author)
  • P. Dongiovanni - (Author)
  • A.L. Fracanzani - (Author)
  • F. Stickel - (Author)
  • J. Hampe - , Department of Internal Medicine I (Author)
  • S. Buch - , Department of Internal Medicine I (Author)
  • P.K. Luukkonen - (Author)
  • D. Prati - (Author)
  • H. Yki-Järvinen - (Author)
  • S. Petta - (Author)
  • C. Xing - (Author)
  • C. Schafmayer - (Author)
  • E. Aigner - (Author)
  • C. Datz - (Author)
  • R.G. Lee - (Author)
  • L. Valenti - (Author)
  • D. Lindén - (Author)
  • S. Romeo - (Author)

Abstract

Fatty liver disease (FLD) is a growing health issue with burdening unmet clinical needs. FLD has a genetic component but, despite the common variants already identified, there is still a missing heritability component. Using a candidate gene approach, we identify a locus (rs71519934) at the Pleckstrin and Sec7 domain-containing 3 (PSD3) gene resulting in a leucine to threonine substitution at position 186 of the protein (L186T) that reduces susceptibility to the entire spectrum of FLD in individuals at risk. PSD3 downregulation by short interfering RNA reduces intracellular lipid content in primary human hepatocytes cultured in two and three dimensions, and in human and rodent hepatoma cells. Consistent with this, Psd3 downregulation by antisense oligonucleotides in vivo protects against FLD in mice fed a non-alcoholic steatohepatitis-inducing diet. Thus, translating these results to humans, PSD3 downregulation might be a future therapeutic option for treating FLD.

Details

Original languageEnglish
Pages (from-to)60–75
Number of pages16
JournalNature metabolism
Volume4
Issue number1
Publication statusPublished - Jan 2022
Peer-reviewedYes

External IDs

Scopus 85123974742
PubMed 35102341

Keywords

Sustainable Development Goals